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Letters to the EditorTo the Editor:
While most hepatitis C virus (HCV) treatment studies have
focused on genotypes 1–3, genotype 4 studies are lacking, even
though it is common in the Middle East and Africa and has a
growing prevalence elsewhere [1,2]. The most effective genotype
4 treatment currently approved is peginterferon (PegIFN)/ribavir-
in with sofosbuvir. However, both PegIFN and ribavirin carry a
signiﬁcant tolerability burden, and there remains a need for effec-
tive and better tolerated all-oral combinations for genotype 4
treatment.
The combination of daclatasvir (NS5A inhibitor), asunaprevir
(NS3 protease inhibitor), and beclabuvir (BMS-791325) – a non-
nucleoside NS5B polymerase inhibitor with comparable activity
against genotypes 1a, 1b, 3a, 4a, and 5a (50% effective concentra-
tion 3–18 nM) and more variable activity against genotype 6a (9–
125 nM) [3] – has demonstrated sustained virologic response
(SVR) rates >90% in treatment-naïve genotype 1 infection [4].
Each of these agents is active in vitro against genotype 4. We
therefore undertook a randomized, open-label, phase 2a
exploratory evaluation of this regimen in treatment-naïve
patients with genotype 4 infection.
The patients (n = 21) were enrolled at nine sites in the USA as
an expansion of a larger study (ClinicalTrials.gov number
NCT01455090) where the design and methods have been fully
described elsewhere [4]. Brieﬂy, treatment-naïve adults with
chronic genotype 4 HCV infection were randomized 1:1 to receive
a twice-daily oral regimen comprising of 75 mg or 150 mg of
beclabuvir, each with daclatasvir (30 mg) and asunaprevir
(200 mg), for 12 weeks with 48 weeks of post-treatment follow-
up. The primary endpoint was SVR at post-treatment Week 12
(SVR12), deﬁned as HCV RNA below 25 IU/ml (COBAS TaqMan
V2 assay; Roche Molecular Diagnostics, Pleasanton, CA, USA),
with or without target detected. In the primary modiﬁed inten-
tion-to-treat analysis, missing HCV RNA data at post-treatment
Week 12 was considered failure. An imputed analysis with miss-
ing Week 12 SVR data backwards-imputed from the next avail-
able RNA measurement was also performed. Sample size was
not derived on the basis of formal statistical power. At an
assumed population SVR12 of 90%, 12 patients per arm was pre-
dicted to yield an 11% probability of underestimating – and a
28% probability of overestimating – SVR12 by P10%, with a 72%
probability of observing a safety event with an incidence of
10%. Patients with compensated cirrhosis were permitted
although none were enrolled.
Viral subtype was assessed by phylogenetic alignment. Base-
line NS5A amino acid sequences (positions 9–213) were aligned
with 39 genotype 4 sequences from the European HCV Database
(http://euhcvdb.ibcp.fr/euHCVdb/) using the ClustalW algorithm
in the AlignX program of Vector NTI (Invitrogen, Carlsbad, CA,
USA). Neighbor-joining trees (1000 bootstrap replicates) were
generated from these alignments using Mega version 5.05 and
were rooted on the ED43 genotype 4 reference sequence
(Genbank accession number Y11604).
Resistance-associated polymorphisms (RAPs) associated with
reduced susceptibility to daclatasvir (e.g. NS5A-L28, -L30, -Y93
variants), beclabuvir (e.g. NS5B-P495 variants) or asunaprevir
(e.g. NS3-Q80, -D168, -R155 variants) were determined at base-
line by population-based sequencing.
Baseline characteristics were comparable between treatment
arms and are shown in Supplementary Table 1. Overall patients
were white and male (91% and 62% respectively), with a mean
age of 51 years. Ethnic ancestry was not collected for study entry,
but post hoc enquiries established 8/21 patients (38%) to be of
Near or Middle Eastern origin (5 Egyptian, 1 Saudi, 1 Afghan, 1
not speciﬁed). All 21 patients completed randomized therapy
and adherence to study medication was high, with 90% (19/21)
assessed as P95% adherent to all three study drugs, assessed
by pill counts and dosing diaries. There were no virologic failures
or post-treatment rebounds in either treatment arm. HCV RNA
decline was rapid: median (range) log10 change from baseline
at day 7 was 4.39 (4.91, 2.95) IU/ml in the 75 mg beclabuvir
group and 4.01 (5.03, 3.47) IU/ml in the 150 mg group. All
patients had <25 IU/ml by Week 2 on-treatment. Two patients,
one in each treatment arm, were missing data at post-treatment
Week 12 but were conﬁrmed to have <25 IU/ml of HCV RNA at
their next attended visits at post-treatment Weeks 24 and/or
36. SVR12 was therefore achieved by 90.9% (10/11) of patients
receiving beclabuvir 75 mg and by 90.0% (9/10) patients receiving
150 mg in the primary mITT analysis, and by 100% of patients in
both arms by the imputed analysis (Table 1). Concordance
between SVR12 and SVR24 was 100% in the 9 patients in each
arm with available HCV RNA data at both these post-treatment
time points.
There were no serious adverse events, discontinuations for
adverse events, or grade 3–4 adverse events in the study. Fifteen
patients (71%) experienced adverse mild-moderate events, seven
patients in the 75 mg arm and eight in the 150 mg arm; all events
were of mild (11/15 patients) or moderate (4/15) intensity. OnlyJournal of Hepatology 2015 vol. 62 j 1204–1218
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Table 1. Virologic responses.
HCV RNA <25 IU/ml, n/N (%) DCV + ASV + BCV 75 mg DCV + ASV + BCV 150 mg
Week 2 11/11 (100) 10/10 (100)
Week 4 11/11 (100) 10/10 (100)
Week 12 (end of treatment) 11/11 (100) 10/10 (100)
Post-treatment Week 4 (SVR4)
mITTa 8/11 (72.7) 9/10 (90.0)
Post-treatment Week 12 (SVR12) (Primary endpoint)
mITTb 10/11 (90.9) 9/10 (90.0)
Imputed (documented on or after posttreatment Week 12) 11/11 (100) 10/10 (100)
Post-treatment Week 24 (SVR24) (Observed data) 10/10 (100) 9/9 (100)
aThree patients in the beclabuvir 75 mg and one patient in the 150 mg group had missing data at post-treatment Week 4; all four patients achieved SVR12, SVR24, or SVR36.
bOne patient in each group had missing data at post-treatment Week 12, but was established to have an SVR result at their next visits (SVR24 and SVR36).
JOURNAL OF HEPATOLOGYone grade 3 laboratory abnormality was observed: an isolated
incident of hypophosphatemia (1.9 mg/dl; lower limit of nor-
mal = 2.4 mg/dl) was noted at the end of treatment/Week 12 visit
and normalized by post-treatment Week 4. No grade 3 or 4 trans-
aminase or bilirubin elevations were observed, and there was no
evidence of beclabuvir dose-related differences in the regimen
safety proﬁle. Headache, insomnia, nausea and pain were report-
ed in more than 10% of patients (Supplementary Table 2).
In the phylogenetic analysis, virus from most patients
(n = 16) grouped with genotype 4a reference sequences, with
the remainder grouping with 4l (n = 2), 4d, 4n or 4o (n = 1 each;
Supplementary Fig. 1). No baseline RAPs in NS3 or NS5B were
observed. Twelve NS5A RAPs at positions 28, 30 and/or 93 were
identiﬁed in nine patients: L28M (n = 2), L30R (n = 4), L30H
(n = 1), L28M + L30A (n = 1) and L28L/M + L30L/H + Y93Y/C
(n = 1). In a previous study, L28 and L30 substitutions emerged
together in genotype 4 infected patients with virologic failure
who had received daclatasvir combined with PegIFNa and rib-
avirin [5]. A further 22 NS5A polymorphisms were observed at
positions 54, 58, and 62; polymorphisms at these positions are
associated with minimal changes in daclatasvir susceptibility in
replicon assays (<2-fold elevation in EC50). Most patient samples
(n = 19) had a D62E substitution relative to the ED43 reference
strain. Other minor polymorphisms were D62N (n = 1), P58T
(n = 1) and P58S (n = 1). These RAPs did not affect virologic
response in this study and all patients achieved SVR.
Thus, in this exploratory study, 12 weeks of twice-daily ther-
apy with daclatasvir, asunaprevir, and beclabuvir (75 mg or
150 mg) resulted in a rapid and sustained decline in HCV virae-
mia in treatment-naïve patients with genotype 4 infection, with
SVR12 rates similar to the 96% SVR12 seen in genotype 4 after
12 weeks of sofosbuvir plus PegIFN/ribavirin [6]. There were no
notable safety or tolerability issues, consistent with previous data
for this regimen with genotype 1 [7]. Thus, this combination of
oral agents for treatment of genotype 4 may potentially provide
an improved safety and tolerability proﬁle compared with cur-
rent PegIFN/ribavirin-containing regimens. It may also offer a tol-
erability advantage compared with several ribavirin-containing
all-oral regimens for genotype 4 which are currently under inves-
tigation [8–10]. Adherence to the three components of the regi-
men (supplied in separate bottles) was high, and may be
further improved by the use of a ﬁxed-dose combination tablet
currently under phase 3 evaluation.
Although baseline RAPs in NS5A were observed in just under
half the patients assessed, there were no on-treatment virologic
failures, and no post-treatment relapses through the primary
endpoint or in any patient for whom post-SVR12 data were avail-
able at time of analysis. A combination of three different
mechanistic classes of direct-acting agent may conceivably
reduce the virological impact of reduced susceptibility to any
one of them, but the overall impact of baseline RAPs on response
to this regimen will require evaluation in a larger dataset.
The primary limitations of this study are its small sample size
and the relatively mild stage of liver disease presented, both of
which limit the extent to which study outcomes can be
extrapolated to the broader virus and patient populations. Cou-
pled with the present results, ongoing phase 3 studies in geno-
type 1 infection will help inform future studies in patients with
genotype 4. Most infections were with genotype 4a, and although
the consistent virologic results in the 24% of patients with non-4a
infections suggest that this regimen will be effective across sub-
types, a larger study in a more diverse range of genotype 4 infec-
tions will be needed to conﬁrm this. In addition, there were no
cirrhotic patients and only four patients with a FibroTest-derived
ﬁbrosis staging above F2 (FibroTest score >0.58). The absence of
patients with advanced liver disease precludes conclusions about
safety or efﬁcacy in this population, although it is relevant that
SVR rates above 90% have subsequently been observed for this
regimen ± ribavirin in genotype 1 infected, treatment-naïve
patients with compensated cirrhosis in the phase 3 UNITY-2
study [11]. The sample size is also insufﬁcient for detection of
low-frequency safety-related events; however, this limitation is
mitigated to some extent by the similarly favorable safety proﬁle
observed with this regimen in larger populations of patients with
genotype 1 infection [7,11,12].
In summary, in this exploratory evaluation, 12 weeks of treat-
ment with the IFN- and ribavirin-free combination of daclatasvir,
asunaprevir and beclabuvir was well tolerated and resulted in a
high rate of SVR in previously untreated patients with chronic
HCV genotype 4 infection, consistent with previous results in
genotype 1.
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